Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 19;11(1):196.
doi: 10.1186/s13578-021-00709-y.

α-Synuclein-mediated neurodegeneration in Dementia with Lewy bodies: the pathobiology of a paradox

Affiliations
Review

α-Synuclein-mediated neurodegeneration in Dementia with Lewy bodies: the pathobiology of a paradox

Christopher Simon et al. Cell Biosci. .

Abstract

Dementia with Lewy bodies (DLB) is epitomized by the pathognomonic manifestation of α-synuclein-laden Lewy bodies within selectively vulnerable neurons in the brain. By virtue of prion-like inheritance, the α-synuclein protein inexorably undergoes extensive conformational metamorphoses and culminate in the form of fibrillar polymorphs, instigating calamitous damage to the brain's neuropsychological networks. This epiphenomenon is nebulous, however, by lingering uncertainty over the quasi "pathogenic" behavior of α-synuclein conformers in DLB pathobiology. Despite numerous attempts, a monolithic "α-synuclein" paradigm that is able to untangle the enigma enshrouding the clinicopathological spectrum of DLB has failed to emanate. In this article, we review conceptual frameworks of α-synuclein dependent cell-autonomous and non-autonomous mechanisms that are likely to facilitate the transneuronal spread of degeneration through the neuraxis. In particular, we describe how the progressive demise of susceptible neurons may evolve from cellular derangements perpetrated by α-synuclein misfolding and aggregation. Where pertinent, we show how these bona fide mechanisms may mutually accentuate α-synuclein-mediated neurodegeneration in the DLB brain.

Keywords: Alzheimer’s disease; Braak hypothesis; Fibrils; Oligomers; Parkinson’s disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
This schematic highlights the regulatory roles of α-synuclein in harmonizing synaptic homeostasis at the presynaptic terminal by coordinating vesicle trafficking, vesicle refilling, and the interactions between vesicle-associated SNARE (v-SNARE), membrane-associated SNARE (t-SNARE), and neurotransmitter release. Figures were created with Biorender.com
Fig. 2
Fig. 2
Under pathological circumstances, α-synuclein aggregation could potentially take place in affiliation with the cellular membrane or in the cytosol. a Membrane-bound monomeric α-synuclein assumes an α-helical structure, but at elevated levels, the monomer endures conformational change to generate membrane-bound β-sheet structures that self-associate to form oligomers and fibrils. b In the cytoplasm, unfolded monomers fluctuate through conformational space to form unstable dimers, which undergo reorganization to generate oligomers of varying morphologies that eventually transform into fibrils. The erratic accretion of these fibrils leads to the amassing of intracytoplasmic Lewy bodies. c During α-synuclein fibrillogenesis, oligomers and amyloid fibrils are immensely noxious, compromising microtubule dynamics, endoplasmic reticulum–Golgi trafficking, and mitochondrial function. Figures were created with Biorender.com
Fig. 3
Fig. 3
Schematic representation of the hypothetical DLB staging construct with stereotyped incursions of α-synuclein pathology across limbic and neocortical networks that might support the occurrence of early dementia with parkinsonism. Figures were created with Biorender.com

Similar articles

Cited by

References

    1. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9(1):13. doi: 10.1038/nrneurol.2012.242. - DOI - PubMed
    1. Kosaka K. Dementia with Lewy bodies. Tokyo: Springer; 2017. History and latest concepts of Lewy body disease and dementia with Lewy bodies; pp. 3–9.
    1. Heidebrink JL. Is dementia with Lewy bodies the second most common cause of dementia? J Geriatr Psychiatry Neurol. 2002;15(4):182–187. doi: 10.1177/2F089198870201500402. - DOI - PubMed
    1. Kane JP, Surendranathan A, Bentley A, Barker SA, Taylor J-P, Thomas AJ, Allan LM, McNally RJ, James PW, McKeith IG. Clinical prevalence of Lewy body dementia. Alzheimer’s Res Ther. 2018;10(1):19. doi: 10.1186/s13195-018-0350-6. - DOI - PMC - PubMed
    1. Mueller C, Ballard C, Corbett A, Aarsland D. The prognosis of dementia with Lewy bodies. Lancet Neurol. 2017;16(5):390–398. doi: 10.1016/s1474-4422(17)30074-1. - DOI - PubMed

LinkOut - more resources